Capronate use of 17-hydroxy-19-norprogesterone as injectable contraceptive depot.

Authors

  • Hilario Hurtado Departamento de Ginecología y Obstetricia, Facultad de Medicina, Universidad Nacional Mayor de San Marcos, Lima, Perú
  • Esteban Kesseru Departamento de Ginecología y Obstetricia, Facultad de Medicina, Universidad Nacional Mayor de San Marcos, Lima, Perú
  • Alfredo Larrañaga Departamento de Ginecología y Obstetricia, Facultad de Medicina, Universidad Nacional Mayor de San Marcos, Lima, Perú

DOI:

https://doi.org/10.31403/rpgo.v14i1457

Abstract

The authors have studied the contraceptive effect of 17-Alpha Hydroxi-19-Norprogesterona Capronate (SN - 582) in 21 normal women; the effect is present during 6-8 weeks after the inyection of 200 mg. During this time menstrual irregularities as spotting and amenorrhea were observed, but their incidence was lower than those produced by the norethisterone enanthate (SN - 393).

Downloads

Download data is not yet available.

Downloads

Published

2015-07-20

Issue

Vol. 14 No. 2 (1968)

Section

Congreso

License

Esta revista provee acceso libre inmediato a su contenido bajo el principio de que hacer disponible gratuitamente la investigación al publico, lo cual fomenta un mayor intercambio de conocimiento global.

Most read articles by the same author(s)